IMMUNOCORE HLDGS PLC's ticker is IMCR and the CUSIP is 45258D105. A total of 123 filers reported holding IMMUNOCORE HLDGS PLC in Q2 2023. The put-call ratio across all filers is 0.18 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $20,366,331 | +17.0% | 600,954 | +124.4% | 0.01% | +28.6% |
| Q1 2024 | $17,406,155 | +324.6% | 267,787 | +346.3% | 0.01% | +250.0% |
| Q4 2023 | $4,099,063 | -68.3% | 59,998 | -75.9% | 0.00% | -71.4% |
| Q3 2023 | $12,942,926 | +232.1% | 249,382 | +283.7% | 0.01% | +250.0% |
| Q2 2023 | $3,897,400 | +43070.1% | 65,000 | -64.4% | 0.00% | -60.0% |
| Q1 2023 | $9,028 | -60.0% | 182,603 | -53.9% | 0.01% | -61.5% |
| Q4 2022 | $22,584 | -99.7% | 395,728 | +153.4% | 0.01% | +225.0% |
| Q3 2022 | $7,331,000 | +268.8% | 156,182 | +193.1% | 0.00% | +300.0% |
| Q2 2022 | $1,988,000 | +105.2% | 53,278 | +64.4% | 0.00% | 0.0% |
| Q1 2022 | $969,000 | -72.1% | 32,400 | -65.5% | 0.00% | -50.0% |
| Q3 2021 | $3,478,000 | -13.6% | 93,812 | -9.0% | 0.00% | 0.0% |
| Q2 2021 | $4,027,000 | -53.6% | 103,121 | -49.4% | 0.00% | -66.7% |
| Q1 2021 | $8,670,000 | – | 203,655 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bill & Melinda Gates Foundation | 576,923 | $39,415,379 | 43.85% |
| RTW INVESTMENTS, LP | 6,096,387 | $416,505,160 | 6.51% |
| Paradigm Biocapital Advisors LP | 1,453,883 | $99,329,287 | 4.65% |
| Rock Springs Capital Management LP | 2,661,507 | $181,834,158 | 4.48% |
| GREAT POINT PARTNERS LLC | 293,000 | $20,017,760 | 3.41% |
| First Turn Management, LLC | 343,079 | $23,439,157 | 3.37% |
| TANG CAPITAL MANAGEMENT LLC | 405,600 | $27,710,592 | 2.56% |
| Logos Global Management LP | 400,000 | $27,328,000 | 2.55% |
| COWEN AND COMPANY, LLC | 536,487 | $36,652,791 | 2.40% |
| Eschler Asset Management LLP | 40,000 | $2,732,800 | 2.17% |